Sirona Biochem Announces Approval of TFChem Acquisition and Closing of Private Placement
Sirona Biochem Corp. (TSX-V: SBM), a biotechnology company specializing in therapeutics for diabetes and obesity, has obtained the final acceptance of the TSX Venture Exchange for the definitive agreement to acquire TFChem...
- Sirona Biochem Closes Non-Brokered Private Placement
- Sirona Biochem to Close Private Placement
- Sirona Biochem Extends Warrant Expiry Dates
- Sirona Biochem Hires Sean Cunliffe as Chief Business Officer
- Sirona Biochem Announces Approval of TFChem Acquisition and Closing of Private Placement